

HR 7008

Pre-approval Information Exchange Act of 2022

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 9, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Mar 10, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/7008>

Sponsor

Name: Rep. Guthrie, Brett [R-KY-2]

Party: Republican • **State:** KY • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Griffith, H. Morgan [R-VA-9]	R · VA		Mar 30, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 10, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Mar 9, 2022)

Pre-approval Information Exchange Act of 2022

This bill specifies that economic, scientific, or other product support information that is exchanged between drug manufacturers and health care entities (e.g., pharmacy benefit managers) about drug products before regulatory approval is not considered to be misbranding or prohibited premarket promotion if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.

Actions Timeline

- **Mar 10, 2022:** Referred to the Subcommittee on Health.
- **Mar 9, 2022:** Introduced in House
- **Mar 9, 2022:** Referred to the House Committee on Energy and Commerce